Symbols / CPIX
CPIX Chart
About
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an injection for the prevention of nausea and vomiting for patients receiving chemotherapy treatment; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of the cardiomyopathy associate with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and aspirin-exacerbated respiratory disease; and is in Phase II clinical trial for the treatment of systemic sclerosis and idiopathic pulmonary fibrosis. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 58.64M |
| Enterprise Value | 53.35M | Income | -3.33M | Sales | 41.28M |
| Book/sh | 1.75 | Cash/sh | 1.02 | Dividend Yield | — |
| Payout | 0.00% | Employees | 91 | IPO | — |
| P/E | — | Forward P/E | 28.00 | PEG | — |
| P/S | 1.42 | P/B | 2.25 | P/C | — |
| EV/EBITDA | 39.91 | EV/Sales | 1.29 | Quick Ratio | 1.05 |
| Current Ratio | 1.23 | Debt/Eq | 39.68 | LT Debt/Eq | — |
| EPS (ttm) | -0.24 | EPS next Y | 0.14 | EPS Growth | — |
| Revenue Growth | -8.70% | Earnings | 2026-03-03 | ROA | -2.86% |
| ROE | -13.28% | ROIC | — | Gross Margin | 84.49% |
| Oper. Margin | -23.70% | Profit Margin | -8.06% | Shs Outstand | 14.96M |
| Shs Float | 8.64M | Short Float | 0.87% | Short Ratio | 0.34 |
| Short Interest | — | 52W High | 7.25 | 52W Low | 1.85 |
| Beta | -0.53 | Avg Volume | 205.56K | Volume | 93.88K |
| Target Price | — | Recom | None | Prev Close | $3.84 |
| Price | $3.92 | Change | 2.08% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$3.92
Latest analyst target
3. DCF / Fair value
$6.86
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.92
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2019-12-03 | main | B. Riley Securities | — → Buy | $10 |
| 2019-11-18 | main | B. Riley Securities | — → Buy | $9 |
| 2018-08-17 | main | B. Riley Securities | Buy → Buy | $9 |
| 2018-04-17 | init | B. Riley Securities | — → Buy | $9 |
| 2013-04-10 | main | UBS | — → Neutral | $6 |
| 2012-11-12 | main | UBS | — → Neutral | $5 |
| 2012-11-09 | down | Wells Fargo | Outperform → Market Perform | — |
- CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH - PR Newswire ue, 04 Nov 2025 08
- Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Passes Above 200 Day Moving Average - Should You Sell? - MarketBeat ue, 17 Feb 2026 05
- $CPIX stock is up 19% today. Here's what we see in our data. - Quiver Quantitative Mon, 15 Dec 2025 08
- Little Excitement Around Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Revenues As Shares Take 31% Pounding - simplywall.st Fri, 06 Feb 2026 08
- With Cumberland Pharmaceuticals Stock Surging, Have You Considered The Downside? - Trefis Sun, 21 Dec 2025 08
- Cumberland Pharmaceuticals (Nasdaq: CPIX) to Report Q3 2025 Results, Hosting Investor Call - Stock Titan ue, 28 Oct 2025 07
- Medtech Stocks Surge in After-Hours Trading: RxSight, Penumbra, and Evolus Take the Lead - Intellectia AI Wed, 18 Feb 2026 15
- Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Crosses Above Two Hundred Day Moving Average - Time to Sell? - MarketBeat Fri, 06 Feb 2026 08
- Cumberland Pharmaceuticals Stock On Fire: Up 76% With 5-Day Winning Streak - Trefis Fri, 19 Dec 2025 08
- CPIX Stock Price and Chart — NASDAQ:CPIX - TradingView Sat, 08 Mar 2025 08
- symbol__ Stock Quote Price and Forecast - CNN Sun, 03 Mar 2024 23
- Cumberland Pharmaceuticals (NASDAQ:CPIX) shareholders are still up 67% over 1 year despite pulling back 10% in the past week - simplywall.st hu, 22 Jan 2026 08
- Whale Trades: Can CPIX weather a recession - Quarterly Portfolio Report & Stock Market Timing Techniques - mfd.ru hu, 12 Feb 2026 10
- $4M for 30% stake: RedHill Biopharma partners with Cumberland to co-commercialize Talicia in U.S. - Stock Titan Mon, 20 Oct 2025 07
- Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date - PR Newswire ue, 05 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 270 | 799 | — | Purchase at price 2.24 - 4.32 per share. | JONES JAMES R | Director | — | 2025-12-31 00:00:00 | D |
| 1 | 66 | 202 | — | Purchase at price 2.24 - 4.32 per share. | YOUNG CAROLINE R | Director | — | 2025-12-31 00:00:00 | D |
| 2 | 1916 | 5653 | — | Purchase at price 2.24 - 4.32 per share. | KROGULSKI KENNETH J | Director | — | 2025-12-31 00:00:00 | D |
| 3 | 270 | 799 | — | Purchase at price 2.24 - 4.32 per share. | KAZIMI A. J. | Chief Executive Officer | — | 2025-12-31 00:00:00 | D |
| 4 | 302 | 664 | — | Purchase at price 1.96 - 2.82 per share. | JONES JAMES R | Director | — | 2025-11-28 00:00:00 | D |
| 5 | 75 | 170 | — | Purchase at price 1.96 - 2.82 per share. | YOUNG CAROLINE R | Director | — | 2025-11-28 00:00:00 | D |
| 6 | 2027 | 4420 | — | Purchase at price 1.96 - 2.82 per share. | KROGULSKI KENNETH J | Director | — | 2025-11-28 00:00:00 | D |
| 7 | 302 | 664 | — | Purchase at price 1.96 - 2.82 per share. | KAZIMI A. J. | Chief Executive Officer | — | 2025-11-28 00:00:00 | D |
| 8 | 299 | 1022 | — | Purchase at price 3.14 - 3.63 per share. | JONES JAMES R | Director | — | 2025-10-31 00:00:00 | D |
| 9 | 138 | 472 | — | Purchase at price 3.14 - 3.63 per share. | YOUNG CAROLINE R | Director | — | 2025-10-31 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 806.10 | 172.58K | 128.38K | 0.00 |
| TaxRateForCalcs | 0.00 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -54.67K | 1.66M | -278.41K | -857.83K |
| TotalUnusualItems | 237.09K | 821.80K | 611.33K | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 237.09K | 821.80K | 611.33K | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -6.48M | -6.28M | -5.57M | -5.50M |
| ReconciledDepreciation | 6.04M | 5.77M | 5.33M | 4.61M |
| ReconciledCostOfRevenue | 5.29M | 8.40M | 8.86M | 8.58M |
| EBITDA | 182.42K | 2.49M | 332.92K | -857.83K |
| EBIT | -5.86M | -5.62M | -5.00M | -5.46M |
| NetInterestIncome | -271.06K | -381.01K | -487.59K | -71.95K |
| InterestExpense | 605.51K | 667.86K | 586.00K | 98.03K |
| InterestIncome | 334.44K | 286.85K | 98.41K | 26.08K |
| NormalizedIncome | -6.72M | -6.93M | -6.05M | -5.50M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -6.48M | -6.28M | -5.57M | -3.51M |
| TotalExpenses | 44.30M | 49.11M | 47.72M | 43.66M |
| TotalOperatingIncomeAsReported | -6.43M | -9.55M | -5.70M | -7.68M |
| DilutedAverageShares | 14.06M | 14.30M | 14.56M | 14.90M |
| BasicAverageShares | 14.06M | 14.30M | 14.56M | 14.90M |
| DilutedEPS | -0.46 | -0.44 | -0.38 | -0.24 |
| BasicEPS | -0.46 | -0.44 | -0.38 | -0.24 |
| DilutedNIAvailtoComStockholders | -6.48M | -6.28M | -5.57M | -3.51M |
| NetIncomeCommonStockholders | -6.48M | -6.28M | -5.57M | -3.51M |
| NetIncome | -6.48M | -6.28M | -5.57M | -3.51M |
| MinorityInterests | -36.05K | 51.45K | 79.80K | 95.21K |
| NetIncomeIncludingNoncontrollingInterests | -6.44M | -6.33M | -5.65M | -3.60M |
| NetIncomeDiscontinuousOperations | 0.00 | 1.99M | ||
| NetIncomeContinuousOperations | -6.44M | -6.33M | -5.65M | -5.60M |
| TaxProvision | -22.67K | 45.77K | 68.85K | 34.89K |
| PretaxIncome | -6.47M | -6.28M | -5.58M | -5.56M |
| OtherIncomeExpense | 237.09K | 3.65M | 611.33K | 2.19M |
| OtherNonOperatingIncomeExpenses | 2.83M | 2.19M | ||
| SpecialIncomeCharges | 237.09K | 821.80K | 611.33K | 0.00 |
| OtherSpecialCharges | -237.09K | -821.80K | -611.33K | |
| NetNonOperatingInterestIncomeExpense | -271.06K | -381.01K | -487.59K | -71.95K |
| InterestExpenseNonOperating | 605.51K | 667.86K | 586.00K | 98.03K |
| InterestIncomeNonOperating | 334.44K | 286.85K | 98.41K | 26.08K |
| OperatingIncome | -6.43M | -9.55M | -5.70M | -7.68M |
| OperatingExpense | 37.71M | 43.04M | 38.60M | 34.85M |
| DepreciationAmortizationDepletionIncomeStatement | 4.75M | 8.10M | 5.07M | 4.37M |
| DepreciationAndAmortizationInIncomeStatement | 4.75M | 8.10M | 5.07M | 4.37M |
| Amortization | 4.75M | 8.10M | 5.07M | 4.37M |
| AmortizationOfIntangiblesIncomeStatement | 4.75M | 8.10M | 5.07M | 4.37M |
| ResearchAndDevelopment | 4.82M | 5.83M | 6.69M | 5.68M |
| SellingGeneralAndAdministration | 28.15M | 29.10M | 26.84M | 24.80M |
| SellingAndMarketingExpense | 17.02M | 18.45M | 16.66M | 15.02M |
| GeneralAndAdministrativeExpense | 11.13M | 10.65M | 10.18M | 9.78M |
| OtherGandA | 11.13M | 10.65M | 10.18M | 9.78M |
| GrossProfit | 31.28M | 33.49M | 32.89M | 27.17M |
| CostOfRevenue | 6.59M | 6.07M | 9.12M | 8.81M |
| TotalRevenue | 37.87M | 39.55M | 42.01M | 35.99M |
| OperatingRevenue | 36.54M | 37.51M | 40.68M | 35.05M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 13.95M | 14.12M | 14.37M | 14.74M |
| ShareIssued | 13.95M | 14.12M | 14.37M | 14.74M |
| TotalDebt | 20.57M | 18.43M | 20.96M | 16.06M |
| TangibleBookValue | 3.97M | 6.08M | 4.76M | 17.98M |
| InvestedCapital | 38.13M | 42.39M | 52.47M | 57.81M |
| WorkingCapital | 4.83M | 7.73M | 17.29M | 26.41M |
| NetTangibleAssets | 3.97M | 6.08M | 4.76M | 17.98M |
| CapitalLeaseObligations | 5.30M | 5.64M | 4.76M | 1.06M |
| CommonStockEquity | 22.85M | 29.60M | 36.27M | 42.81M |
| TotalCapitalization | 33.03M | 42.39M | 52.47M | 57.81M |
| TotalEquityGrossMinorityInterest | 22.55M | 29.26M | 35.97M | 42.60M |
| MinorityInterest | -307.52K | -343.57K | -292.13K | -212.33K |
| StockholdersEquity | 22.85M | 29.60M | 36.27M | 42.81M |
| RetainedEarnings | -23.97M | -17.49M | -11.21M | -5.64M |
| CapitalStock | 46.82M | 47.09M | 47.47M | 48.45M |
| CommonStock | 46.82M | 47.09M | 47.47M | 48.45M |
| TotalLiabilitiesNetMinorityInterest | 53.04M | 52.52M | 56.95M | 41.86M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 21.42M | 24.53M | 28.37M | 22.58M |
| OtherNonCurrentLiabilities | 250.00K | 274.00K | 131.00K | 224.79K |
| NonCurrentAccruedExpenses | 2.88M | 3.28M | 4.93M | 3.83M |
| NonCurrentDeferredLiabilities | 3.17M | 2.89M | 2.52M | 3.43M |
| LongTermDebtAndCapitalLeaseObligation | 15.12M | 18.08M | 20.79M | 15.09M |
| LongTermCapitalLeaseObligation | 4.94M | 5.30M | 4.59M | 90.02K |
| LongTermDebt | 10.18M | 12.78M | 16.20M | 15.00M |
| CurrentLiabilities | 31.62M | 27.98M | 28.58M | 19.28M |
| OtherCurrentLiabilities | 8.77M | 9.37M | 11.52M | 4.62M |
| CurrentDeferredLiabilities | 207.06K | 220.40K | 614.55K | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 5.46M | 348.09K | 172.91K | 969.68K |
| CurrentCapitalLeaseObligation | 356.51K | 348.09K | 172.91K | 969.68K |
| CurrentDebt | 5.10M | |||
| OtherCurrentBorrowings | 5.10M | |||
| LineOfCredit | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.20M | 1.20M | 1.44M | 1.34M |
| PayablesAndAccruedExpenses | 15.99M | 16.85M | 14.84M | 12.34M |
| CurrentAccruedExpenses | 2.07M | 2.81M | 4.02M | 2.70M |
| Payables | 13.91M | 14.04M | 10.82M | 9.64M |
| AccountsPayable | 13.91M | 14.04M | 10.82M | 9.64M |
| TotalAssets | 75.58M | 81.78M | 92.93M | 84.46M |
| TotalNonCurrentAssets | 39.13M | 46.06M | 47.05M | 38.77M |
| OtherNonCurrentAssets | 13.79M | 15.50M | 10.05M | 12.47M |
| GoodwillAndOtherIntangibleAssets | 18.89M | 23.52M | 31.50M | 24.84M |
| OtherIntangibleAssets | 17.97M | 22.61M | 30.59M | 23.95M |
| Goodwill | 914.00K | 914.00K | 914.00K | 882.00K |
| NetPPE | 6.45M | 7.04M | 5.50M | 1.47M |
| AccumulatedDepreciation | -2.39M | -2.24M | -2.09M | -3.79M |
| GrossPPE | 8.85M | 9.28M | 7.59M | 5.26M |
| Leases | 7.00M | 7.48M | 6.01M | 2.45M |
| MachineryFurnitureEquipment | 1.84M | 1.81M | 1.58M | 2.81M |
| BuildingsAndImprovements | 1.02M | |||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 36.45M | 35.71M | 45.87M | 45.69M |
| OtherCurrentAssets | 2.79M | 3.03M | 3.08M | 3.34M |
| PrepaidAssets | 3.34M | |||
| Inventory | 4.00M | 4.61M | 9.86M | 8.43M |
| InventoriesAdjustmentsAllowances | -11.01M | -12.80M | -7.53M | -9.05M |
| OtherInventories | 126.09K | 149.70K | 168.92K | 164.38K |
| FinishedGoods | 2.90M | 4.65M | 4.32M | 4.94M |
| RawMaterials | 11.98M | 12.62M | 12.90M | 12.37M |
| Receivables | 11.70M | 9.76M | 13.16M | 6.88M |
| AccountsReceivable | 11.70M | 9.76M | 13.16M | 6.88M |
| AllowanceForDoubtfulAccountsReceivable | -1.10M | -600.00K | -600.00K | -300.00K |
| GrossAccountsReceivable | 12.80M | 10.36M | 13.76M | 7.18M |
| CashCashEquivalentsAndShortTermInvestments | 17.96M | 18.32M | 19.76M | 27.04M |
| CashAndCashEquivalents | 17.96M | 18.32M | 19.76M | 27.04M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -791.90K | 5.64M | 6.38M | 5.99M |
| RepurchaseOfCapitalStock | -579.05K | -740.53K | -1.05M | -1.39M |
| RepaymentOfDebt | -36.00M | -34.89M | -51.70M | -59.00M |
| IssuanceOfDebt | 38.49M | 31.48M | 52.90M | 59.00M |
| CapitalExpenditure | -179.71K | -453.05K | -2.07M | -354.46K |
| InterestPaidSupplementalData | 569.23K | 647.14K | 523.16K | 63.98K |
| IncomeTaxPaidSupplementalData | 15.00K | 108.82K | 3.30K | |
| EndCashPosition | 17.96M | 18.32M | 19.76M | 27.04M |
| BeginningCashPosition | 18.32M | 19.76M | 27.04M | 24.75M |
| ChangesInCash | -357.44K | -1.44M | -7.28M | 2.29M |
| FinancingCashFlow | 196.90K | -7.42M | -2.06M | -3.55M |
| CashFlowFromContinuingFinancingActivities | 196.90K | -7.42M | -2.06M | -3.55M |
| NetOtherFinancingCharges | -1.72M | -3.27M | -2.21M | -2.17M |
| NetCommonStockIssuance | -579.05K | -740.53K | -1.05M | -1.39M |
| CommonStockPayments | -579.05K | -740.53K | -1.05M | -1.39M |
| NetIssuancePaymentsOfDebt | 2.49M | -3.42M | 1.20M | 0.00 |
| NetShortTermDebtIssuance | 0.00 | |||
| ShortTermDebtPayments | -59.00M | |||
| ShortTermDebtIssuance | 59.00M | |||
| NetLongTermDebtIssuance | 2.49M | -3.42M | 1.20M | 0.00 |
| LongTermDebtPayments | -36.00M | -34.89M | -51.70M | -59.00M |
| LongTermDebtIssuance | 38.49M | 31.48M | 52.90M | 59.00M |
| InvestingCashFlow | 57.84K | -105.69K | -13.67M | -501.89K |
| CashFlowFromContinuingInvestingActivities | 57.84K | -105.69K | -13.67M | -501.89K |
| NetOtherInvestingChanges | 237.56K | 347.36K | 1.90M | 52.57K |
| NetInvestmentPurchaseAndSale | 0.00 | -200.00K | ||
| SaleOfInvestment | 0.00 | |||
| PurchaseOfInvestment | 0.00 | -200.00K | ||
| NetBusinessPurchaseAndSale | 0.00 | -13.50M | 0.00 | |
| PurchaseOfBusiness | 0.00 | -13.50M | 0.00 | |
| NetIntangiblesPurchaseAndSale | -113.25K | -171.78K | -1.97M | -250.93K |
| PurchaseOfIntangibles | -113.25K | -171.78K | -1.97M | -250.93K |
| NetPPEPurchaseAndSale | -66.46K | -281.27K | -102.15K | -103.53K |
| PurchaseOfPPE | -66.46K | -281.27K | -102.15K | -103.53K |
| OperatingCashFlow | -612.19K | 6.09M | 8.45M | 6.34M |
| CashFromDiscontinuedOperatingActivities | 0.00 | 1.99M | ||
| CashFlowFromContinuingOperatingActivities | -612.19K | 6.09M | 8.45M | 4.35M |
| ChangeInWorkingCapital | 1.29M | 4.63M | 10.44M | 8.18M |
| ChangeInOtherCurrentLiabilities | -1.15M | -2.54M | 419.66K | -1.34M |
| ChangeInOtherCurrentAssets | 189.11K | 65.68K | 689.26K | -35.57K |
| ChangeInPayablesAndAccruedExpense | 1.78M | 3.72M | 14.54M | -757.59K |
| ChangeInPayable | 1.78M | 3.72M | 14.54M | -757.59K |
| ChangeInAccountPayable | 1.78M | 3.72M | 14.54M | -757.59K |
| ChangeInInventory | 2.41M | -23.14K | 911.08K | 4.82M |
| ChangeInReceivables | -1.94M | 3.40M | -6.12M | 5.50M |
| ChangesInAccountReceivables | -1.94M | 3.40M | -6.12M | 5.50M |
| OtherNonCashItems | -1.81M | -1.71M | -2.11M | -3.39M |
| StockBasedCompensation | 301.89K | 365.04K | 447.50K | 741.87K |
| AssetImpairmentCharge | 0.00 | 3.34M | 0.00 | |
| DeferredTax | 0.00 | 0.00 | ||
| DeferredIncomeTax | 0.00 | 0.00 | ||
| DepreciationAmortizationDepletion | 6.04M | 5.77M | 5.33M | 4.61M |
| DepreciationAndAmortization | 6.04M | 5.77M | 5.33M | 4.61M |
| AmortizationCashFlow | 5.07M | 4.37M | ||
| AmortizationOfIntangibles | 5.07M | 4.37M | ||
| Depreciation | 6.04M | 5.77M | 5.33M | 235.07K |
| OperatingGainsLosses | 2.69K | 20.26K | -2.19M | |
| NetIncomeFromContinuingOperations | -6.44M | -6.33M | -5.65M | -3.60M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CPIX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|